The inverted pyramid of biomarker-driven trials

被引：0
|
作者：
Ignacio Garrido-Laguna
Manuel Hidalgo
Razelle Kurzrock
机构：
[1] The University of Texas MD Anderson Cancer Center,Departments of Investigational Cancer Therapeutics (A Phase I Program)
[2] Gastrointestinal Cancer Clinical Research Unit,undefined
[3] Spanish National Cancer Research Center,undefined
来源：
Nature Reviews Clinical Oncology | 2011年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Phase I trials have evolved from simple dose-finding studies to studies that provide therapeutic opportunities for patients where no standard therapy is available; however, various factors have hampered patient recruitment on phase I trials. The authors discuss how matching patients with specific genetic aberrations to specific therapies will improve drug attrition rates and improve patient outcomes.
引用
收藏
页码：562 / 566
页数：4
相关论文
共 50 条
  • [1] The inverted pyramid of biomarker-driven trials
    Garrido-Laguna, Ignacio
    Hidalgo, Manuel
    Kurzrock, Razelle
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (09) : 562 - 566
  • [2] BIOMARKER-DRIVEN TRIALS IN EARLY DRUG DEVELOPMENT
    Fine, B. M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 22 - 22
  • [3] Challenges and opportunities in biomarker-driven trials: adaptive randomization
    Park, Yeonhee
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
  • [4] Biomarker-driven patient selection for early clinical trials
    Dienstmann, Rodrigo
    Rodon, Jordi
    Tabernero, Josep
    [J]. CURRENT OPINION IN ONCOLOGY, 2013, 25 (03) : 305 - 312
  • [5] STRATIFICATION AND PARTIAL ASCERTAINMENT OF BIOMARKER VALUE IN BIOMARKER-DRIVEN CLINICAL TRIALS
    Simon, Richard
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (05) : 1011 - 1021
  • [6] From drug discovery to biomarker-driven clinical trials in lymphoma
    Younes, Anas
    Berry, Donald A.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (11) : 643 - 653
  • [7] From drug discovery to biomarker-driven clinical trials in lymphoma
    Anas Younes
    Donald A. Berry
    [J]. Nature Reviews Clinical Oncology, 2012, 9 : 643 - 653
  • [8] Biomarker-driven clinical trials for anti-cancer drug development
    Kim, Dong-Wan
    [J]. CANCER SCIENCE, 2023, 114 : 1703 - 1703
  • [9] Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials?
    Yendamuri, Sai
    Dragnev, Konstantin H.
    [J]. CANCER PREVENTION RESEARCH, 2024, 17 (09) : 399 - 400
  • [10] A risk management approach for imaging biomarker-driven clinical trials in oncology
    Liu, Yan
    deSouza, Nandita M.
    Shankar, Lalitha K.
    Kauczor, Hans-Ulrich
    Trattnig, Siegfried
    Collette, Sandra
    Chiti, Arturo
    [J]. LANCET ONCOLOGY, 2015, 16 (16): : E622 - E628
12345